Cancer Advisor

From “Undruggable” to One of the Most Important Targets in Cancer Medicine For decades, KRAS mutations were considered one of the most challenging problems in oncology. The protein was structurally smooth, biologically complex, and notoriously resistant to drug binding. It became known in medical literature as “undruggable.” That narrative changed dramatically in the early 2020s. Today, KRAS is no longer a scientific dead end—it is one of the most actively targeted oncogenic drivers in modern precision medicine. Multiple generations of KRAS inhibitors now exist, and treatment strategies are evolving from single-mutation targeting toward pan-RAS pathway control and combination therapy systems . However, despite major breakthroughs, KRAS-driven cancers remain difficult to cure. The reason is not a lack of drugs—but the adaptability of cancer biology itself. Update (May 2026): Daraxonrasib Pancreatic Cancer Drug : New RAS Inhibitor Doubles Survival in Phase 3 Trial This article provides a...

Authors: Yuan Yuan, Jin Sun Bitar, MaLia Walker, David Lin, January Lee, So Yung Choi, Stephen Shiao, Mourad Tighiouart, Paul H. Frankel, Peter P. Lee Affiliation: Cedars-Sinai Medical Center, Los Angeles, CA Abstract e13146 (2025 ASCO Annual Meeting) is a phase 1/2 study of ivermectin in combination with balstilimab after 1-2 prior lines of therapy for triple negative breast cancer ( J Clin Oncol 2025 ) Background: Despite recent FDA approval of immune checkpoint inhibitor (ICI) and antibody-drug conjugates (ADCs), therapeutic options for metastatic triple negative breast cancer (mTNBC) remain limited. Preclinical data showed that ivermectin induces robust T cell infiltration into breast tumors and turning “cold” tumors “hot” in mouse model of TNBC. Balstilimab is a fully humanized IgG4 anti-PD-1 agent with proven safety and efficacy in metastatic cervical cancer. The current phase I/II trial is designed to test the safety and efficacy of the combination of ivermectin and balsti...

Evidence review updated: September 2026 Bottom line: EnteroMix is a genuine experimental Russian cancer immunotherapy, but it is not an approved cancer cure and it is not the same thing as Russia's personalized mRNA cancer-vaccine programme. EnteroMix is an oncolytic virotherapy based on four enteroviruses . As of 2026, the publicly registered human evidence remains an early Phase I study focused primarily on safety, tolerability, pharmacokinetics and dose selection. Claims of "100% efficacy," dramatic tumour regression, or a proven cancer cure go substantially beyond the publicly verifiable clinical evidence. Important: EnteroMix should not be confused with Russia's separate personalized mRNA cancer-vaccine programme. The two technologies have different mechanisms, development programmes and evidentiary status. Contents 1. What is EnteroMix? 2. The critical correction: EnteroMix is not the mRNA vaccine 3. How EnteroMix is intended to work ...

When it comes to managing or preventing prostate cancer, what you put on your plate matters far more than most people realize. While there is no single miracle food that can cure or completely block the disease, a mountain of modern research shows that a targeted, plant-forward diet can help slow cancer progression, lower the risk of recurrence, and protect your heart during treatment. Whether you are focusing on prevention, currently navigating active surveillance, or managing side effects from therapies like hormone treatment, this updated guide breaks down the science-backed foods to lean into—and the ones you should consider leaving on the shelf. Top Cancer-Fighting Foods to Add to Your Plate A high-performing prostate health diet focuses on reducing systemic inflammation and packing your body with natural antioxidants. Start prioritizing these dietary staples: 1. Cooked Tomatoes (Rich in Lycopene) Tomatoes are packed with lycopene , a powerful antioxidant that gives red fr...

OneDayMD Oncology Intelligence • 2026 Update From Keytruda and CAR-T to antibody-drug conjugates, radioligand therapy and Gendicine gene therapy. Reviewed/updated: September 2026 The global cancer-treatment industry is entering a new era. Oncology is no longer defined simply by chemotherapy and conventional small-molecule drugs. The modern cancer-treatment ecosystem includes immune checkpoint inhibitors, targeted therapies, antibody-drug conjugates (ADCs), bispecific antibodies, CAR-T cells, radioligand therapies, protein degraders, cancer vaccines, oncolytic viruses and gene therapies. This updated 2026 review therefore looks beyond a simple sales ranking. It evaluates the world's leading cancer-drug and biotechnology companies according to oncology commercial scale, therapeutic innovation, pipeline strength, platform technology, strategic importance and potential influence on the future of cancer treatment . Key takeaway: ...